The World Intellectual Property Organization’s (WIPO) 42nd session of the Intergovernmental Committee on Genetic Resources, Traditional Knowledge, and Folklore (IGC) meets from 28 February 2022 to 4 March 2022. The focus of WIPO’s work this week is to finalize an… Continue Reading
On Tuesday, 1 March 2022, Knowledge Ecology International delivered the following statement at the 42nd session of the WIPO Intergovernmental Committee on Genetic Resources, Traditional Knowledge, and Folklore. KEI would like some clarifications regarding how regimes proposed in the IGC… Continue Reading
This is a letter from the three prostate cancer patient petitioners to HHS Secretary Becerra and Acting NIH Director Tabak, regarding the February 9, 2020 statement by Astellas on the Bayh-Dole march in and government rights case. The patient’s letter… Continue Reading
The Special 301 Subcommittee of the Trade Policy Staff Committee has sent a document with questions to everyone who provided comments on the Special 301 list. The questions are attached and are also available at https://www.regulations.gov/comment/USTR-2021-0021-0065. The deadline to submit… Continue Reading
Senators Elizabeth Warren (D-MA) and Angus King (I-ME) and Representative Lloyd Doggett (D-TX) wrote Secretary of HHS Xavier Becerra on February 17, 2022, urging him to move forward with the march-in petition by Robert Sachs, Clare Love and Eric Sawyer,… Continue Reading
(More on the Xtandi case here: https://www.keionline.org/xtandi2021) Astellas has issued a statement, dated February 9, 2022, on the Bayh-Dole Act and the petition to exercise march-in and government use rights in the prostate cancer drug Xtandi. It was brought to… Continue Reading
(Update: The NIH provided a response to our questions and comments on February 28, 2022) On February 9, 2022, Knowledge Ecology International (KEI) filed comments with the National Institutes of Health regarding the “Prospective Grant of Exclusive Patent License: Development… Continue Reading
In a January 31, 2022 letter to Drew Hirshfeld, the Commissioner for Patents for the USPTO, and Janet Woodcock, the Acting Commissioner of the FDA, Senator Thom Tillis provides extensive criticism of the empirical work of the group I-MAK and… Continue Reading
Following the publication of the US government contract with Pfizer for the COVID-19 therapeutic Paxlovid, the petitioners of the Xtandi government use request wrote to the Department of Health and Human Services (HHS) and the National Institutes of Health (NIH)… Continue Reading
The Department of Health and Human Services (HHS) and National Institutes of Health (NIH) is currently reviewing whether to proceed with the request that the government use its rights in the prostate cancer drug Xtandi, in order to enable generic… Continue Reading